Transvenous endocardial pacing with SelectSecure
3830 lead
Endocardial pacing
Infants
Lumenless
Right ventricular septal pacing
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
06
08
2023
accepted:
28
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
epublish
Résumé
The SelectSecure™ 3830 lead is an innovative, lumenless, and thin active fixed lead with a nonretractable screw-in tip and a diameter of 4.1 Fr, making it the thinnest pacing lead available. Its high anti-extrusion properties and durability have shown favorable outcomes in cardiac pacing, especially in pediatric patients. The superfine design and easy implantation of the lead have rendered it a preferred choice in children, particularly in cases of congenital heart disease. This case series presents two infant patients who underwent transvenous endocardial pacing using the SelectSecure™ 3830 lead, along with a comprehensive literature review on the topic. The study followed the patients for 5 years and 3 years, respectively, and observed stable pacing parameters, indicating a positive therapeutic outcome and safety. This article discusses the optimal age and body shape for transvenous lead implantation in infants and highlights the advantages and disadvantages of endocardial and epicardial pacing approaches. Although endocardial pacing offers several benefits such as minimal trauma, short hospital stay, and longer battery life, it may not be suitable for intracardiac shunts, and venous occlusion remains a concern. On the other hand, epicardial pacing may be considered for children with challenging endocardial access but comes with higher risk of lead failure and coronary artery compression. This study emphasizes the importance of careful follow-up in pediatric patients with pacing, as lead failure can occur in young patients owing to growth and development, leading to syncope and battery depletion. The article also underscores the significance of selecting the appropriate pacing location to minimize the impact of cardiac function, with right ventricular septal pacing emerging as a preferable option. The SelectSecure™ 3830 lead presents a promising solution for transvenous endocardial pacing in pediatric patients with high degree atrioventricular block and bradycardia, ensuring safe and effective pacing as they grow and develop.
Sections du résumé
BACKGROUND
BACKGROUND
The SelectSecure™ 3830 lead is an innovative, lumenless, and thin active fixed lead with a nonretractable screw-in tip and a diameter of 4.1 Fr, making it the thinnest pacing lead available. Its high anti-extrusion properties and durability have shown favorable outcomes in cardiac pacing, especially in pediatric patients. The superfine design and easy implantation of the lead have rendered it a preferred choice in children, particularly in cases of congenital heart disease.
CASE PRESENTATION
METHODS
This case series presents two infant patients who underwent transvenous endocardial pacing using the SelectSecure™ 3830 lead, along with a comprehensive literature review on the topic. The study followed the patients for 5 years and 3 years, respectively, and observed stable pacing parameters, indicating a positive therapeutic outcome and safety. This article discusses the optimal age and body shape for transvenous lead implantation in infants and highlights the advantages and disadvantages of endocardial and epicardial pacing approaches. Although endocardial pacing offers several benefits such as minimal trauma, short hospital stay, and longer battery life, it may not be suitable for intracardiac shunts, and venous occlusion remains a concern. On the other hand, epicardial pacing may be considered for children with challenging endocardial access but comes with higher risk of lead failure and coronary artery compression. This study emphasizes the importance of careful follow-up in pediatric patients with pacing, as lead failure can occur in young patients owing to growth and development, leading to syncope and battery depletion. The article also underscores the significance of selecting the appropriate pacing location to minimize the impact of cardiac function, with right ventricular septal pacing emerging as a preferable option.
CONCLUSIONS
CONCLUSIONS
The SelectSecure™ 3830 lead presents a promising solution for transvenous endocardial pacing in pediatric patients with high degree atrioventricular block and bradycardia, ensuring safe and effective pacing as they grow and develop.
Identifiants
pubmed: 38443792
doi: 10.1186/s12872-024-03820-3
pii: 10.1186/s12872-024-03820-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Informations de copyright
© 2024. The Author(s).
Références
Ng LY, Gallagher S, Walsh KP. Case series of late lead dislodgement of Medtronic SelectSecure 3830 pacing leads in growing paediatric patients. Eur Heart J Case Rep. 2021;5(2):ytaa545. https://doi.org/10.1093/ehjcr/ytaa545 .
doi: 10.1093/ehjcr/ytaa545
pmcid: 7873804
Fortescue EB, Berul CI, Cecchin F, Walsh EP, Triedman JK, Alexander ME. Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm. 2004;1(2):150–9. https://doi.org/10.1016/j.hrthm.2004.02.020 .
doi: 10.1016/j.hrthm.2004.02.020
Ergul Y, Yukcu B, Ozturk E, Kafali HC, Ayyildiz P, Ergun S, et al. Evaluation of different lead types and implantation techniques in pediatric populations with permanent pacemakers: single-center with 10 years’ experience. Pacing Clin Electrophysiol. 2021;44(1):110–9. https://doi.org/10.1111/pace.14126 .
doi: 10.1111/pace.14126
De Filippo P, Giofrè F, Leidi C, Senni M, Ferrari P. Transvenous pacing in pediatric patients with bipolar lumenless lead: ten-year clinical experience. Int J Cardiol. 2018;255:45–9. https://doi.org/10.1016/j.ijcard.2018.01.007 .
doi: 10.1016/j.ijcard.2018.01.007
Khan A, Zelin K, Karpawich PP. Performance of the lumenless 4.1-Fr diameter pacing lead implanted at alternative pacing sites in congenital heart: a chronic 5-year comparison. Pacing Clin Electrophysiol. 2010;33(12):1467–74. https://doi.org/10.1111/j.1540-8159.2010.02884.x .
doi: 10.1111/j.1540-8159.2010.02884.x
Bansal N, Samuel S, Zelin K, Karpawich PP. Ten-year clinical experience with the Lumenless, Catheter-Delivered, 4.1-Fr diameter pacing lead in patients with and without congenital heart. Pacing Clin Electrophysiol. 2017;40(1):17–25. https://doi.org/10.1111/pace.12995 .
doi: 10.1111/pace.12995
Zartner PA, Wiebe W, Toussaint-Goetz N, Schneider MB. Lead removal in young patients in view of lifelong pacing. Europace. 2010;12(5):714–8. https://doi.org/10.1093/europace/euq059 .
doi: 10.1093/europace/euq059
Garnreiter J, Whitaker P, Pilcher T, Etheridge S, Saarel E. Lumenless pacing leads: performance and extraction in pediatrics and congenital heart disease. Pacing Clin Electrophysiol. 2015;38(1):42–7. https://doi.org/10.1111/pace.12508 .
doi: 10.1111/pace.12508
Daccarett M, Segerson NM, Bradley DJ, Etheridge SP, Freedman RA, Saarel EV. Bipolar lumenless lead performance in children and adults with congenital heart disease. Congenit Heart Dis. 2010;5(2):149–56. https://doi.org/10.1111/j.1747-0803.2009.00374.x .
doi: 10.1111/j.1747-0803.2009.00374.x
Küçük M, Balli S, Karadag H. Experience with implantation of Select Secure(®) leads in paediatric patients. Acta Cardiol. 2023;78(6):665–71. https://doi.org/10.1080/00015385.2022.2051878 .
doi: 10.1080/00015385.2022.2051878
Konta L, Chubb MH, Bostock J, Rogers J, Rosenthal E. Twenty-seven years experience with transvenous pacemaker implantation in children weighing < 10 kg. Circulation: Arrhythmia Electrophysiol. 2016;9(2):e003422.
Antretter H, Colvin J, Schweigmann U, Hangler H, Hofer D, Dunst K, et al. Special problems of pacing in children. Indian Pacing Electrophysiol J. 2003;3(1):23–33.
pmcid: 1555629
Patsiou V, Haidich AB, Baroutidou A, Giannopoulos A, Giannakoulas G. Epicardial Versus Endocardial Pacing in Paediatric patients with atrioventricular block or sinus node dysfunction: a systematic review and Meta-analysis. Pediatr Cardiol. 2023;44(8):1641–8. https://doi.org/10.1007/s00246-023-03213-x .
doi: 10.1007/s00246-023-03213-x
pmcid: 10520152
Silvetti MS, Drago F, Di Carlo D, Placidi S, Brancaccio G, Carotti A. Cardiac pacing in paediatric patients with congenital heart defects: transvenous or epicardial? Europace. 2013;15(9):1280–6. https://doi.org/10.1093/europace/eut029 .
doi: 10.1093/europace/eut029
Odim J, Suckow B, Saedi B, Laks H, Shannon K. Equivalent performance of epicardial versus endocardial permanent pacing in children: a single institution and manufacturer experience. Ann Thorac Surg. 2008;85(4):1412–6. https://doi.org/10.1016/j.athoracsur.2007.12.075 .
doi: 10.1016/j.athoracsur.2007.12.075
Song L, Meng Q, Liu C, Wang G, Wang H, Zhou G, et al. Experience of treating congenital complete atrioventricular block with epicardial pacemaker in infants and young children: a retrospective study. BMC Cardiovasc Disord. 2023;23(1):575. https://doi.org/10.1186/s12872-023-03620-1 .
doi: 10.1186/s12872-023-03620-1
pmcid: 10664347
Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK, et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. J Cardiovasc Electrophysiol. 2006;17(7):754–9. https://doi.org/10.1111/j.1540-8167.2006.00489.x .
doi: 10.1111/j.1540-8167.2006.00489.x
Vos LM, Kammeraad JAE, Freund MW, Blank AC, Breur J. Long-term outcome of transvenous pacemaker implantation in infants: a retrospective cohort study. Europace. 2017;19(4):581–7. https://doi.org/10.1093/europace/euw031 .
doi: 10.1093/europace/euw031
Dardari M, Cinteza E, Vasile CM, Padovani P, Vatasescu R. Infective endocarditis among Pediatric patients with prosthetic valves and Cardiac devices: a review and update of recent Emerging Diagnostic and Management Strategies. J Clin Med. 2023;12(15). https://doi.org/10.3390/jcm12154941 .
Wilhelm BJ, Thöne M, El-Scheich T, Livert D, Angelico R, Osswald B. Complications and Risk Assessment of 25 years in Pediatric Pacing. Ann Thorac Surg. 2015;100(1):147–53. https://doi.org/10.1016/j.athoracsur.2014.12.098 .
doi: 10.1016/j.athoracsur.2014.12.098
Takeuchi D, Tomizawa Y. Pacing device therapy in infants and children: a review. J Artif Organs. 2013;16(1):23–33. https://doi.org/10.1007/s10047-012-0668-y .
doi: 10.1007/s10047-012-0668-y
Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337–82. https://doi.org/10.1093/europace/eut082 .
doi: 10.1093/europace/eut082
Kubus P, Materna O, Gebauer RA, Matejka T, Gebauer R, Tláskal T, et al. Permanent epicardial pacing in children: long-term results and factors modifying outcome. Europace. 2012;14(4):509–14. https://doi.org/10.1093/europace/eur327 .
doi: 10.1093/europace/eur327
Mah DY, Prakash A, Porras D, Fynn-Thompson F, DeWitt ES, Banka P. Coronary artery compression from epicardial leads: more common than we think. Heart Rhythm. 2018;15(10):1439–47. https://doi.org/10.1016/j.hrthm.2018.06.038 .
doi: 10.1016/j.hrthm.2018.06.038
Cantù F, De Filippo P, Gabbarini F, Borghi A, Brambilla R, Ferrero P, et al. Selective-site pacing in paediatric patients: a new application of the Select Secure system. Europace. 2009;11(5):601–6. https://doi.org/10.1093/europace/eup058 .
doi: 10.1093/europace/eup058
Richardson TD, Himes A, Marshall M, Crossley GH. Rationale for and use of the lumenless 3830 pacing lead. J Cardiovasc Electrophysiol. 2023;34(3):769–74. https://doi.org/10.1111/jce.15828 .
doi: 10.1111/jce.15828
Hussain MA, Furuya-Kanamori L, Kaye G, Clark J, Doi SA. The effect of right ventricular apical and Nonapical Pacing on the short- and long-term changes in left ventricular ejection fraction: a systematic review and Meta-analysis of randomized-controlled trials. Pacing Clin Electrophysiol. 2015;38(9):1121–36. https://doi.org/10.1111/pace.12681 .
doi: 10.1111/pace.12681
Cano Ó, Andrés A, Alonso P, Osca J, Sancho-Tello MJ, Olagüe J, et al. Incidence and predictors of clinically relevant cardiac perforation associated with systematic implantation of active-fixation pacing and defibrillation leads: a single-centre experience with over 3800 implanted leads. Europace. 2017;19(1):96–102. https://doi.org/10.1093/europace/euv410 .
doi: 10.1093/europace/euv410